Role of Regulatory B Cells in the Pathogenesis of Metabolic Associated Fatty Liver Disease

To evaluate the role of regulatory B cells in the pathogenesis of metabolic associated fatty liver disease patients.

Study Overview

• Status: Recruiting
• Conditions: Non-Alcoholic Fatty Liver Disease
• Intervention / Treatment: Diagnostic test: regulatory B cell by flow cytometry

Detailed Description

The prevalence of non-alcoholic fatty liver disease (NAFLD) increases rapidly in recent decades. NAFLD has become a major public health problem in the whole world, and it is considered as the main cause for the chronic liver diseases (Feng, 2020).

Eslam et al. (2020) recently published an international expert consensus statement about a new definition of metabolic dysfunction-associated fatty liver disease (MAFLD) to replace non-alcoholic fatty liver disease (NAFLD).

The new nomenclature of MAFLD is based on the presence of steatosis in >5% of hepatocytes and the absence of excessive alcohol consumption or other causes of chronic liver disease, diagnosis of MAFLD could be established on the presence of hepatic steatosis in combination with one of the following three criteria: overweight/obesity; presence of type 2 diabetes mellitus; or evidence of metabolic dysregulation (Eslam et al. (2020).

Metabolic dysregulation is defined as having at least 2 of the following metabolic risk abnormalities: high waist circumference, high blood pressure, high cholesterol, pre-diabetes, insulin resistance, and high plasma C-reactive protein levels (Eslam et al. (2020).

New diagnostic criteria for MAFLD were proposed, in which hepatic steatosis (HS) detected either by imaging techniques, blood biomarkers/scores or by liver histology (Bedogni et al., 2006; Wong et al., 2019).

On the other hand, NAFLD is commonly associated with one or more component of metabolic syndrome such as obesity, diabetes mellitus, and dyslipidemia and is defined as the presence of ≥ 5% hepatic steatosis in histological examination without evidence of hepatocellular injury such as hepatocyte ballooning (Chalasani et al., 2018).

Around 20% of patients with NAFLD develop non-alcoholic steatohepatitis (NASH) which may progress to cirrhosis, however the most common cause of death in NAFLD patients is cardiovascular disease, and NAFLD is the third most common cause of hepatocellular carcinoma (Matteoni et al., 1999; Chalasani et al., 2018).

The spectrum of NAFLD ranges from simple fatty liver with little inflammation to non-alcoholic steatohepatitis (NASH) with liver inflammation and fibrosis. The global prevalence of NAFLD is about 25.2% whereas the limited number of studies from Africa reports 13% (Younossi et al., 2016).

"Burned out" NAFLD can be a hidden cause of cryptogenic cirrhosis. So, early diagnosis, and treatment of NAFLD and underlying predisposing factors are important to avoid liver damage which may progress to liver cell failure (Paul, 2020).

NAFLD is strongly associated with MS and is currently considered as the hepatic manifestation of MS. In addition, obesity is a common risk factor for NAFLD (fan et al., 2008; Chen et al., 2011; Medina-Santillán et al., 2013).

Liver is not only the largest metabolic organ, but also it act as an immunological organ. Immune cells including liver resident macrophages )Kupffer cells, KCs( and lymphocytes account for 10-20% of total cells in the liver (Racanelli et al., 2006; Gao et al., 2008).

These immune cells cross the blood from gastrointestinal tract, which contains abundant antigens from outside and sometime pathogens under pathological conditions, to maintain a unique immune tolerance microenvironment (Racanelli et al., 2006).

However, when excessive fat deposited in the hepatocytes and metabolic status was changed, the immune microenvironment was found to be also changed. Numerous studies indicated that different immune cells in the liver (both innate and adaptive) played critical roles in the pathogenesis of NAFLD and NASH(Feng, 2020).

Innate immune system includes KCs/infiltrated macrophages, neutrophils, dendritic cells (DCs), natural killer (NK) cells, while adaptive immune system includes conventional T cells, natural killer T (NKT) cells and B cells(Feng, 2020).

Smith et al. (2003) examined healthy human donor livers and detected the B cells located in the portal tracts and those scattered throughout the liver.

B cells are specialized adaptive immune cells producing antibodies, it can also secrete cytokines and regulate the activation and function of other cells. Little studies focused on the role of B cells in the pathogenesis of NAFLD, especially direct effects. One study showed that increased production of T-helper 1 cell (Th1) cytokines, such as IL-6 and TNF-a, which were found in intrahepatic B cells in mice fed with high-fat diet. These cytokines may promote Th1 cell differentiation and contribute to inflammation in NAFLD (Zhang et al., 2016).

As regard role of B cells in the pathogenesis of metabolic syndrome (MS) which promote inflammation in obesity and type 2 diabetes mellitus (T2DM) through modulation of T-cell function and an inflammatory cytokine profile and they also promote insulin resistance (IR) through the production of pathogenic IgG2a. Meanwhile, B cells can regulate T cells via a major histocompatibility complex-dependent manner and promote inflammation mediated by T cells in both obese mice and T2DM patients (Jagannathan et al., 2009; Winer et al., 2011; DeFuria et al., 2013).

NAFLD is strongly associated with MS and is currently considered as the hepatic manifestation of MS. In addition, obesity is a common risk factor for NAFLD (fan et al., 2008; Chen et al., 2011; Medina-Santillán et al., 2013).

Surprisingly, IgA, which is mainly produced by B cells, has been reported to be positively related to the stages of fibrosis in patients with NAFLD. The B cell activating factor (BAFF), which regulates the development and maturation of B cells, was found to be increased in the serum of patients with non-alcoholic steatohepatitis (NASH). All these results indicate that there are systemic changes in B cells in patients with NAFLD (Kim et al., 2009; Miyake et al., 2013; McPherson et al., 2014).

Based on the changes in humoral factors in NAFLD and the roles of B cells in MS, we hypothesized that B cells might participate in the pathogenesis of NAFLD. So, our study aimed to focus on B cells, to investigate its general changes and their functions in the pathogenesis of the disease.

• Study Type: Observational
• Enrollment (Estimated): 174

Contacts and Locations

• Study Contact: Name: Amira Mohamed, PhD; Phone Number: 0101276047; Email: amiramohmad60@gmail.com

Study Locations

• Egypt
  • Assiut, Egypt
    • Recruiting
    • Medicine
    • Contact: Amira Mohamed, PhD; Phone Number: 01012760437; Email: amiramohmad60@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

1. After obtaining the appropriate consents, data pertaining to clinical history (name, age, sex, residence, occupation, co-morbidities… diabetes, hyperlipidemia, hypertension, ischemic heart disease, special habits; such as alcohol intake).
2. Imaging techniques, such as ultrasonography (US), fibroscan with CAP and/or computed topography (CT) and /or MRI.
3. Blood samples will be collected for liver function tests, lipid profile and CRP.
4. Evaluation of the Frequency of regulatory B cells (Bregs) by Flow Cytometry
5. Six measurements will be obtained (sex, age, height, weight, body mass index, and abdominal girth, waist circumference).

Calculation of fatty liver index, (FLI) will be done. The fatty liver index (FLI), is an algorithm based on waist circumference, body mass index (BMI), triglyceride, and gamma-glutamyl-transferase (GGT).

Description

Inclusion Criteria:

• All patients aged >18 years old and was diagnosed as fatty liver based on clinical examination, laboratory investigations and imaging techniques.

Exclusion Criteria:

• 1-Patients aged ≤18 years old. 2-Pregnancy. 3-Presence of malignancy. 4-Type I DM. 5-Fatty liver patients on treatment by statin derivatives or other medications. 6- Fatty liver patients undergone bariatric surgeries.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Role of regulatory B cells in the pathogenesis of metabolic associated fatty liver disease	To evaluate the role of regulatory B cells in the pathogenesis of metabolic associated fatty liver disease patients.	baseline

Collaborators and Investigators

• Sponsor: Assiut University

Publications and helpful links

General Publications

• Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018 Feb;68(2):305-315. doi: 10.1016/j.jhep.2017.11.013. Epub 2017 Dec 2.

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2023
• Primary Completion (Estimated): February 1, 2024
• Study Completion (Estimated): September 1, 2024

Study Registration Dates

• First Submitted: January 11, 2021
• First Submitted That Met QC Criteria: January 19, 2021
• First Posted (Actual): January 22, 2021

Study Record Updates

• Last Update Posted (Actual): January 30, 2024
• Last Update Submitted That Met QC Criteria: January 29, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Liver Diseases; Fatty Liver; Non-alcoholic Fatty Liver Disease
• Other Study ID Numbers: MAFLD

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No